Migraine Drugs Market

Table of Contents

1 Introduction
    1.1 Objective of the Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Markets Covered
           1.3.2 Years Considered in the Study
    1.4 Stakeholders

2 Research Methodology
    2.1 Market Size Estimation
    2.2 Market Crackdown and Data Triangulation
    2.3 Market Share Estimation
           2.3.1 Key Data Points Taken From Secondary Sources
           2.3.2 Key Data Points Taken From Primary Sources
    2.4 Assumptions

3 Executive Summary

4 Premium Insights

5 Market Overview
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Drivers
           5.2.2 Restraints
           5.2.3 Opportunities
           5.2.4 Challenges

6 Migraine Drugs Market, By Product Type
    6.1 Introduction
    6.2 Acute Migraine Treatment
           6.2.1 Analgesic
           6.2.2 Ergotamine
           6.2.3 Triptans
    6.3 Preventive Migraine Treatment 
           6.3.1  Beta Blockers
           6.3.2 Anti-Serotonergic Drugs
           6.3.3 Antidepressants
           6.3.4  Anti-Convulsants
           6.3.5 Calcium Channel Blockers
           6.3.6 Others

7 Migraine Drugs Market, By Route of Administration
    7.1 Introduction
    7.2 Oral
    7.3 Injection
    7.4 Others

9 Migraine Drugs Market, By End User
    9.1 Introduction
    9.2 Hospitals Based Pharmacies
    9.3 Retail Pharmacies
    9.4 Online Pharmacies

10 Migraine Drugs Market, By Region
     10.1 Introduction
     10.2 North America
             10.2.1 US
             10.2.2 Canada
     10.3 Europe
             10.3.1 Germany
             10.3.2 UK
             10.3.3 France
             10.3.4 Rest of Europe (RoE)
     10.4 Asia Pacific
             10.4.1 China
             10.4.2 India
             10.4.3 Japan
             10.4.4 Rest of Asia Pacific
     10.5 Rest of the World (RoW)

11 Competitive Landscape
     11.1 Introduction
     11.2 Market Share Analysis
     11.3 Competitive Situation and Trends

12 Company Profiles*
     12.1 Introduction
     12.2 Abbott Labrotatories 
     12.3 Allergan 
     12.4 Amgen
     12.5 Glaxosmithkline
     12.6 Pfizer.
     12.7 Eli Lilly 
     12.8 Aegis Therapeutics, LLC.
     12.9 Johnson & Johnson
     12.10 Astrazeneca PLC

Note: *Details on Financials, Products & Services, Key Strategy, & Recent Developments Might Not Be Captured in Case of Unlisted Companies.
* 10 to 15 Market Leaders Will Be Profiled
* Segmentation May Change During the Planned Research Work

The global Migrane Drugs market is expected to reach USD 3.96 billion by 2023 from USD 1.95 million in 2018, growing at a CAGR of 15.2%. Increasing awareness about novel therapies, launch of Calcitonin Gene-related Peptide (CGRP), increasing incidence of migraines and launch of new drugs are some of the major factors driving the growth of the global suture anchor market. These driving factors consequence to the rapid adoption of these new drugs, thus propelling the market growth.

North America dominates the migraine drugs market with the North America accounted major market share in 2017. Established healthcare infrastructure; and increasing demand for preventive migraine treatment options are some of the major driving factors driving the growth of this market in North America. The Asian migraine drugs market is poised to grow at the highest CAGR during the forecast period owing to improving healthcare infrastructure and rising awareness about novel treatments among people in the region. The rising focus of prominent players on the Asian migraine drugs market is another factor driving its growth. Furthermore, emerging countries such as India and China provides immense growth opportunities to the migraine drug manufacturers.

Prominent players in the suture anchor devices market Abbott Laboratories (U.S.), Allergan  (Ireland), Amgen (U.S.), GlaxoSmithKline (UK), Pfizer (U.S.), Eli Lilly (U.S.), Aegis Therapeutics, LLC. (U.S.), Johnson and Johnson (U.S.), and AstraZeneca PLC. (UK).

Scope of the Report

This research report covers the global Migraine Drugs market by method; product type; route of administration; end user; and geography.

Migraine Drugs Market, by Product Type

• ACute  migraine treatment
  • ANALGESIC
  • ERGOTAMINE
  • TRIPTANS
• Preventive migraine treatment
  • BEta Blockers
  • Anti-serotonergic drugs
  • ANTIDEPRESSANTS
  • Anti-convulsants
  • Calcium Channel Blockers
  • OTHERS

Migraine Drugs Market, by Route of Administration

• oral
• injection
• OTHERS

Migrane Drugs Market, by End User

• hospitals based pharmacies
• retail pharmacies
• online pharmacies

Migrane Drugs Market, BY region

• North america
  • US
  • Canada
• Europe
  • germany
  • uk
  • france
  • italy
  • rest of europe (roe)
• Asia pacific
  • china
  • india
  • japan
  • rest of asia pacific
• Rest of the world (roW)